- Eupraxia Pharmaceuticals Inc. announced the pricing of a public offering of **12,727,273** common shares at **US$5.50** per share, aiming for gross proceeds of approximately **US$70 million**.  **[1581178_0001171843-25-006031_exh_991.htm:0]** 
- The company has granted the underwriters a 30-day option to purchase up to an additional **1,909,090** common shares.  **[1581178_0001171843-25-006031_exh_991.htm:0]** 
- The offering is expected to close on **September 24, 2025**, subject to customary closing conditions.  **[1581178_0001171843-25-006031_exh_991.htm:0]** 
- The net proceeds from the offering will primarily be used for the continued advancement of its product pipeline, including preclinical studies, clinical trials, regulatory submissions, and manufacturing scale-up, as well as for research and development of additional pipeline candidates and general corporate purposes.  **[1581178_0001171843-25-006031_exh_991.htm:0]**

Eupraxia Pharmaceuticals Prices US$70 Million Public Offering

- Eupraxia Pharmaceuticals Inc. (EPRX) announced **positive 1-year clinical data** from its Phase 1b/2a RESOLVE trial for **EP-104GI** in treating eosinophilic esophagitis (EoE).  **[1581178_0001171843-25-005662_exh_991.htm:0]** 
- At 12 months, **two-thirds of Cohort 5 patients** (48mg dose, 4mg per site) remained in clinical remission, and all cohorts followed to 9 months maintained clinically meaningful improvements in tissue health.  **[1581178_0001171843-25-005662_exh_991.htm:0]** 
- The trial reported **no Serious Adverse Events (SAE)** or any events of oral or gastrointestinal candidiasis to date.  **[1581178_0001171843-25-005662_exh_991.htm:0]** 
- The company expects to report **additional 12-month data** from a larger patient set later this year and anticipates top-line data from the Phase 2b part of the RESOLVE trial in **Q3 2026**.  **[1581178_0001171843-25-005662_exh_991.htm:0]** **[1581178_0001171843-25-005662_exh_991.htm:1]**

EUPRAXIA PHARMACEUTICALS (EPRX)